CHARLES B. SIMONE, II, M.D. JOINS THE NEW YORK PROTON CENTER AS CHIEF MEDICAL OFFICER
Internationally recognized as a leading expert in the use of proton therapies, Dr. Simone will be instrumental in opening the Manhattan facility in Spring 2019
Charles B Simone II, MD, Medical Director of New York Proton Treatment Center June 5, 2019 ABC News Interview
Charles B Simone II, M.D. Ribbon Cutting Ceremony for New York Proton Center June 6, 2019
October 10, 2018, Manhattan, NY – Today, the New York Proton Center announced Dr. Charles B. Simone, II will join the organization as its Chief Medical Officer. Before taking the position, he was the Medical Director of the Maryland Proton Treatment Center and an Associate Professor of Radiation Oncology at the University of Maryland School of Medicine, where he also served as the Director of the Stereotactic Radiation Therapy Program and the Fellowship Director for the Department of Radiation Oncology.
The New York Proton Center will open in Spring 2019 to deliver one of the world’s most advanced cancer treatments in a single center of excellence located in Manhattan. Offering the first and only facility for proton therapy in New York State, the center has partnered with leading academic medical centers in New York—Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, and Mount Sinai Health System—each of which is committed to ensuring the accessibility of this technology for patients in the state of New York.
“I’m so very excited to be joining the New York Proton Center. The center represents the coming together of three truly world class institutions and boasts the most advanced proton therapy technology available,” said Dr. Simone. “Using pencil-beam scanning, the New York Proton Center team will target tumors with unmatched precision while minimizing damage to surrounding healthy tissues. I look forward to being able to provide patients in New York, the Tri-State Area and beyond with the very best possible care.”
Dr. Simone is a National Institutes of Health, National Science Foundation, and Department of Defense funded investigator who performs clinical and translational research investigating the benefits of proton therapy as part of multi-modality therapy for thoracic malignancies. He has published more than 265 peer-reviewed scientific articles and book chapters and given more than 165 scientific lectures to national and international audiences.
“We are so pleased Dr. Simone will be joining our team of dedicated physicians and care teams to provide a patient-centered approach to treatment,” said Allan Freeman, Sr. Vice President of Project Development of the New York Proton Center. “He is internationally recognized as the leading expert in the use of proton therapies, the development of clinical trial strategies, and innovative research in thoracic radiation oncology, stereotactic body radiation therapy, and reirradiation.”
Dr. Simone completed his undergraduate and medical school training at the University of Pennsylvania. He completed an internship in internal medicine, and then he completed residency training in radiation oncology at the National Cancer Institute, National Institutes of Health, where he served as chief resident. He is the Chair of the Proton Collaborative Group (PCG) Executive Committee, Chair of the PCG Lung Committee, Chair of the American Society for Radiation Oncology (ASTRO) Lung Resource Panel Committee, and Chair of the American Society for Photobiology (ASP) Education Committee. He is appointed to the NRG Oncology (formerly Radiation Therapy Oncology Group [RTOG]) Lung Cancer Core Committee; NRG Radiation Oncology Committee; NCI Thoracic Malignancies Steering Committee Mesothelioma Working Group; International Thymic Malignancy Interest Group (ITMIG) Research and Infrastructure Committee; ITMIG Thymic Carcinoma Workgroup; International Mesothelioma Interest Group (iMig) Scientific Committee; ASTRO Lung Cancer “Blue Ribbon” Panel; ASTRO Guidelines Committee; American College of Radiation Oncology (ACRO) Scientific Program Committee; American Radium Society (ARS) Scientific Program Committee; ASP Executive Council; PCG Reirradiation Committee; Particle Therapy Co-Operative Group (PTCOG) Scientific Committee; and multiple PTCOG Clinical Subcommittees. He has led numerous innovative clinical trials and authored clinical practice guidelines on proton therapy, lung cancer, and other thoracic malignancies for PTCOG, PCG, ASTRO, ARS, and the American College of Radiology.
ABOUT NEW YORK PROTON CENTER
The New York Proton Center is committed to creating the gold standard for proton therapy and giving patients a new hope in their fight against cancer. In partnership with leading academic medical centers in New York—Memorial Sloan-Kettering Cancer Center, Montefiore Medical Center, and Mount Sinai Health System—the New York Proton Center brings together expert oncologists, clinical care teams, and researchers into a single center of excellence to improve cancer care and advance the clinical evidence for proton therapy.
To learn more about the New York Proton Center, please contact Patrick Curry at (646) 968-9071.